841 related articles for article (PubMed ID: 23215720)
21. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
Narayanankutty A
Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
[TBL] [Abstract][Full Text] [Related]
22. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
23. Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.
De P; Miskimins K; Dey N; Leyland-Jones B
Cancer Treat Rev; 2013 Aug; 39(5):403-12. PubMed ID: 23352077
[TBL] [Abstract][Full Text] [Related]
24. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
25. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives.
Corti F; Nichetti F; Raimondi A; Niger M; Prinzi N; Torchio M; Tamborini E; Perrone F; Pruneri G; Di Bartolomeo M; de Braud F; Pusceddu S
Cancer Treat Rev; 2019 Jan; 72():45-55. PubMed ID: 30476750
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
28. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.
O'Regan R; Hawk NN
Expert Opin Ther Targets; 2011 Jul; 15(7):859-72. PubMed ID: 21476875
[TBL] [Abstract][Full Text] [Related]
29. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
30. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Blachly JS; Baiocchi RA
Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
[TBL] [Abstract][Full Text] [Related]
31. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
Zardavas D; Fumagalli D; Loi S
Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
[TBL] [Abstract][Full Text] [Related]
32. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.
Gonzalez-Angulo AM; Blumenschein GR
Cancer Treat Rev; 2013 Jun; 39(4):313-20. PubMed ID: 23218708
[TBL] [Abstract][Full Text] [Related]
33. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
Han Y; Wang J; Wang Z; Xu B
Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
[TBL] [Abstract][Full Text] [Related]
35. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
36. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
Hernandez-Aya LF; Gonzalez-Angulo AM
Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
[TBL] [Abstract][Full Text] [Related]
37. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
[TBL] [Abstract][Full Text] [Related]
38. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
39. α-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice.
Wang F; Ma H; Liu Z; Huang W; Xu X; Zhang X
Biomed Pharmacother; 2017 Aug; 92():672-680. PubMed ID: 28582759
[TBL] [Abstract][Full Text] [Related]
40. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.
Cidado J; Park BH
J Mammary Gland Biol Neoplasia; 2012 Dec; 17(3-4):205-16. PubMed ID: 22865098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
